Patent classifications
A61K31/452
Methods for inhibiting conversion of choline to trimethylamine (TMA)
The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): ##STR00001##
wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.
Charged ion channel blockers and methods for use
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
Charged ion channel blockers and methods for use
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
Novel compounds for use in treating depression and migraine
The invention relates to amide-derivatives of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid for use in a treatment for preventing or suppressing symptoms associated with mood disorders, headaches and migraine. The compounds of the invention can be used to treat any subject suffering from a mood disorder, headaches and/or migraine but can specifically be used to treat a mood disorder, headaches and/or migraine in patients suffering from a mitochondrial disease.
Novel compounds for use in treating depression and migraine
The invention relates to amide-derivatives of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid for use in a treatment for preventing or suppressing symptoms associated with mood disorders, headaches and migraine. The compounds of the invention can be used to treat any subject suffering from a mood disorder, headaches and/or migraine but can specifically be used to treat a mood disorder, headaches and/or migraine in patients suffering from a mitochondrial disease.
CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:
##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:
##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS
Derivatives of N,N-diethyl-N-phenyl-piperazine, a silent agonist of the mammalian 7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.